For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Sinusitis, also known as a sinus infection or rhinosinusitis, is inflammation of the sinuses resulting in symptoms. Common signs and symptoms include thick nasal mucus, a plugged nose, and pain in the face. Other signs and symptoms may include fever, headaches, poor sense of smell, sore throat, and cough. The cough is often worse at night. Serious complications are rare. It is defined as acute rhinosinusitis (ARS) if it lasts less than 4 weeks, and chronic rhinosinusitis (CRS) if it lasts for more than 12 weeks. Drugs for Sinusitis are common in the market, and the drugs can also be used in other disease. These drugs can not cure sinusitis, can only relieve symptoms.
Scope of the Report:
This report focuses on the Drugs for Sinusitis in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The classification of Drugs for Sinusitis includes Antibiotics, Corticosteroids, Decongestants and other. And the revenue proportion of Corticosteroids in 2015 is nearly 31%.
Drugs for Sinusitis are widely used in Neurology, Orthopedics, Musculoskeletal &Spine, Cardiology & Vascular, Skin & Integumentary, and other field. The most proportion of Drugs for Sinusitis is Orthopedics, Musculoskeletal &Spine, and the revenue in 2015 is 2387.4 M USD.
North America region is the largest supplier of Drugs for Sinusitis, with a revenue market share nearly 35% in 2015. Europe is the second largest supplier of Drugs for Sinusitis, enjoying revenue market share nearly 27% in 2015.
North America is the largest consumption place, with a consumption market share nearly 35% in 2015. Following North America, Europe is the second largest consumption place with the consumption market share of 24%.
Sanofi, Bayer AG, Pfizer etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
The worldwide market for Drugs for Sinusitis is expected to grow at a CAGR of roughly 3.6% over the next five years, will reach 2410 million US$ in 2023, from 1950 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Bayer AG
- AstraZeneca Plc
- Novartis AG.
- Johnson & Johnson
- Bionorica SE
- Dr. Reddy's Laboratories
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
- Acute Sinusitis
- Chronic Sinusitis
There are 15 Chapters to deeply display the global Drugs for Sinusitis market.
Chapter 1, to describe Drugs for Sinusitis Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Drugs for Sinusitis, with sales, revenue, and price of Drugs for Sinusitis, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Drugs for Sinusitis, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Drugs for Sinusitis market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Drugs for Sinusitis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source